Jul 24 2012
Elan Corporation, plc (NYSE:ELN) announced today that Pfizer has issued
a top-line result in the first of four Bapineuzumab Phase 3 studies
carried out by Pfizer and Janssen AI.
As referenced in the Pfizer announcement, Study 302 is the first of four
placebo-controlled Phase 3 studies to complete a comprehensive
development program of bapineuzumab IV. Jansen AI is leading two Phase 3
studies of patients who are ApoE4 carriers (Study 302) and non-carriers
(Study 301) at sites primarily in North America. Pfizer is conducting
two Phase 3 studies of patients who are ApoE4 carriers (Study 3001) and
non - carriers (Study 3000) at sites primarily outside North America.
As further referenced in the announcement, the topline results from
Study 301 in patients with mild - to - moderate Alzheimer's who do not
carry the ApoE4 genotype will soon be available.
In September 2009, as a result of its transaction with Johnson &
Johnson, Elan acquired a 49.9% interest in Janssen AI.